ArticleOncology and therapy2025

Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study.

Dana M Chase et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.